Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab bronchoscopic intratumoral injection followed by first-line sintilimab plus platinum doublet chemotherapy for advanced NSCLC
ChiCTR2100054479Phase 4Recruiting
- Sponsor
- Qiqihar First Hospital
- Start
- Nov 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab, cisplatin, carboplatin, pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Qiqihar First Hospital. Primary endpoint: Objective response rate. Started Nov 2021; status: recruiting.
02
Drugs
sintilimabcisplatincarboplatinpemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100054479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054479.